MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
종목 코드 MNKD
회사 이름MannKind Corp
상장일Jul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
직원 수407
유형Ordinary Share
회계 연도 종료Jul 28
주소1 Casper Street
도시DANBURY
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호06810
전화18186615000
웹사이트https://mannkindcorp.com/
종목 코드 MNKD
상장일Jul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음